CervoMed Inc. (NASDAQ:CRVO) — Market Cap & Net Worth
Market Cap & Net Worth: CervoMed Inc. (CRVO)
CervoMed Inc. (NASDAQ:CRVO) has a market capitalization of $37.95 Million ($37.95 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23014 globally and #5037 in its home market, demonstrating a 1.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CervoMed Inc.'s stock price $2.55 by its total outstanding shares 15119096 (15.12 Million). Also see CervoMed Inc. (CRVO) total assets for a full breakdown of the balance sheet.
CervoMed Inc. Market Cap History: 2015 to 2026
CervoMed Inc.'s market capitalization history from 2015 to 2026. Data shows change from $170.09 Billion to $38.55 Million (-51.69% CAGR). Also see CervoMed Inc. (CRVO) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
CervoMed Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #655 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2170 of 3165 |
Weight: CervoMed Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CervoMed Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CervoMed Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check CRVO stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
29.81x
CervoMed Inc.'s market cap is 29.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $115.36 Million | $7.14 Million | -$2.17 Million | 16.15x | N/A |
| 2024 | $35.38 Million | $9.74 Million | -$16.29 Million | 3.63x | N/A |
| 2025 | $119.44 Million | $4.01 Million | -$26.97 Million | 29.81x | N/A |
Competitor Companies of CRVO by Market Capitalization
Companies near CervoMed Inc. in the global market cap rankings as of September 18, 2026. Review CRVO tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to CervoMed Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
CervoMed Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, CervoMed Inc.'s market cap moved from $170.09 Billion to $ 38.55 Million, with a yearly change of -51.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $38.55 Million | -67.72% |
| 2025 | $119.44 Million | +237.61% |
| 2024 | $35.38 Million | -69.33% |
| 2023 | $115.36 Million | +0.58% |
| 2022 | $114.69 Million | -66.84% |
| 2021 | $345.85 Million | -61.64% |
| 2020 | $901.48 Million | +72.56% |
| 2019 | $522.40 Million | -76.85% |
| 2018 | $2.26 Billion | -88.76% |
| 2017 | $20.07 Billion | -47.79% |
| 2016 | $38.44 Billion | -77.40% |
| 2015 | $170.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of CervoMed Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.95 Million USD |
| MoneyControl | $37.95 Million USD |
| MarketWatch | $37.95 Million USD |
| marketcap.company | $37.95 Million USD |
| Reuters | $37.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and sl… Read more